Treatment of coronary bifurcation lesions with drug-eluting stents: insights from the first phase of the prospective multicenter german drug-eluting stent registry.

BACKGROUND Controversy exists about the impact of treating bifurcations on overall outcome of coronary interventions using drug-eluting stents (DES). We sought to investigate 1-year outcome of the treatment of bifurcation lesions using DES in a large "real-world" cohort. METHODS AND RESULTS Among 5,126 patients enrolled in phase I of the multicenter German Drug-Eluting Stent Registry, 814 (16%) were treated for a bifurcation lesion. Patients with bifurcations were compared to those without bifurcations in terms of baseline characteristics, major adverse cardiac and cerebrovascular events (MACCE) and target vessel revascularization (TVR) at 1 year. Usage of sirolimus-eluting stents (SES) versus paclitaxel-eluting stents (PES) was also evaluated. In total, 1,021 and 5,189 stents were implanted in the bifurcation (1.25 stents/patient) and nonbifurcation (1.2 stents/patient) group, respectively, but 64.5% of bifurcation lesions were treated with a single stent. More complex lesion and procedural characteristics were observed in the bifurcation group. However, there was no difference in 1-year MACCE rates (a composite of death, myocardial infarction, and stroke) between the bifurcation group and nonbifurcation group (8.1% vs. 8.3%, P = 0.85). Rates of TVR (11.2% vs. 10.8%, P = 0.75) and Academic Research Consoritum-defined definite stent thrombosis (0.9% vs. 0.8%, P = 0.67) were also comparable. MACCE and TVR rates remained similar after adjustment for differences in baseline characteristics. MACCE and TVR in SES patients were 7.2% and 12.6% versus 8.7% and 10.2% in PES patients (P = 0.46 and P = 0.30, respectively). CONCLUSION In this large multicenter registry, treatment of bifurcation lesions with DES appears effective and safe. The presence of bifurcations did not affect 1-year outcomes after DES implantation. The outcomes for SES and PES were similar.

[1]  M. Jeong,et al.  Sirolimus- versus paclitaxel-eluting stents for the treatment of coronary bifurcations results: from the COBIS (Coronary Bifurcation Stenting) Registry. , 2010, Journal of the American College of Cardiology.

[2]  A. Baumbach,et al.  Randomized Trial of Simple Versus Complex Drug-Eluting Stenting for Bifurcation Lesions: The British Bifurcation Coronary Study: Old, New, and Evolving Strategies , 2010, Circulation.

[3]  S. Willich,et al.  Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry). , 2009, The American journal of cardiology.

[4]  Dick M. Goedhart,et al.  Three-year clinical outcome of percutaneous treatment of bifurcation lesions in multivessel coronary artery disease with the sirolimus-eluting stent: insights from the Arterial Revascularisation Therapies Study, part II (ARTS II). , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[5]  Antonio Colombo,et al.  Bifurcation disease: what do we know, what should we do? , 2008, JACC. Cardiovascular interventions.

[6]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[7]  Antonio Colombo,et al.  The clinical outcome of percutaneous treatment of bifurcation lesions in multivessel coronary artery disease with the sirolimus-eluting stent: insights from the Arterial Revascularization Therapies Study part II (ARTS II). , 2007, European heart journal.

[8]  H. Bøtker,et al.  Comparison of sirolimus-eluting and bare metal stents in coronary bifurcation lesions: subgroup analysis of the Stenting Coronary Arteries in Non-Stress/Benestent Disease Trial (SCANDSTENT). , 2006, American heart journal.

[9]  M. Niemelä,et al.  Randomized Study on Simple Versus Complex Stenting of Coronary Artery Bifurcation Lesions: The Nordic Bifurcation Study , 2006, Circulation.

[10]  P. Serruys,et al.  Long-term outcomes after stenting of bifurcation lesions with the "crush" technique: predictors of an adverse outcome. , 2006, Journal of the American College of Cardiology.

[11]  B. Gersh.  Incidence, Predictors, and Outcome of Thrombosis After Successful Implantation of Drug-Eluting Stents , 2006 .

[12]  I. Iakovou,et al.  In-hospital and nine-month outcome of treatment of coronary bifurcational lesions with sirolimus-eluting stent. , 2005, The American journal of cardiology.

[13]  P. Serruys,et al.  Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. , 2005, Journal of the American College of Cardiology.

[14]  K. Detre,et al.  Immediate and one-year outcome in patients with coronary bifurcation lesions in the modern era (NHLBI dynamic registry). , 2001, The American journal of cardiology.

[15]  E. Vañó,et al.  Clinical and technical determinants of the complexity of percutaneous transluminal coronary angioplasty procedures: Analysis in relation to radiation exposure parameters , 2000, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[16]  C. Di Mario,et al.  Immediate and long-term results of "T" stenting for bifurcation coronary lesions. , 2000, The American journal of cardiology.

[17]  J. Tobis,et al.  Bifurcation lesions: two stents versus one stent--immediate and follow-up results. , 2000, Journal of the American College of Cardiology.

[18]  H. Hecht,et al.  Lesion morphology and coronary angioplasty: current experience and analysis. , 1992, Journal of the American College of Cardiology.